Eli Lilly and Company (LLY)
Health Care50 articles
Price chart
Why is LLY moving today?
+3.5%LLY is +3.5% today, a large move, and no story about it reached the feed in the last 24 hours. Large moves without a headline are common: index flows, options positioning, a peer's report or a sector rotation can all do it. We do not invent a reason.
What this does not prove. A story on the same day is evidence of timing, not of cause: it explains a move only if it accounts for the size and the direction, and most single-stock moves carry a sector or index component too. Nothing here is a forecast.
Source: Yahoo Finance - quote as of 13 hours ago
Eli Lilly and Company (LLY) overview
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
LLY is a member of the S&P 500. It sits in the Health Care sector. That sector covers pharmaceutical, biotech, device and managed-care companies.
Eli Lilly and Company trades on the NYSE under the ticker symbol LLY. The most recent market data puts the share price at about $1,251.61. That is up 3.55% on the session. At that price the company is worth roughly $1.12T.
Over the past 52 weeks, LLY has traded between $783.85 and $1,292.65. Shares change hands at a trailing price-to-earnings (P/E) ratio of about 42.0. The P/E ratio sets the share price against a year of earnings. A higher number means the market is paying more for each dollar the company earns. LLY also pays a dividend. It yields around 0.55% at the current price.
Key statistics
Source: Yahoo Finance - quote as of 13 hours ago
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch LLY
LLY is one of the larger names in the Health Care sector, so investors follow it closely. It tends to move with the rest of the sector. This page sums up each LLY story as it breaks, and tags it bullish, bearish or neutral.
Size matters here as well. The S&P 500 is weighted by market value. LLY is large enough that its own share price nudges the whole index. So it is worth watching even for investors who only hold index funds.
What moves LLY
- Earnings. LLY reports results four times a year. A surprise against the estimate tends to move the stock that day.
- Analyst calls. Upgrades, downgrades and new price targets change what the market expects from LLY.
- Sector news. Health Care stocks often move together, so a rival's news can move LLY too.
- Index weight. LLY is big enough to move the S&P 500 on its own.
Market Mood
Latest LLY news
Viking Therapeutics (VKTX) Shares Soar on Obesity Drug Data Release
Viking Therapeutics (VKTX) has experienced a significant increase in stock price following positive data regarding its obesity drug. Meanwhile, competitors Eli Lilly and Novo Nordisk saw declines. The specifics regarding the percentage increase in Viking's stock and changes for its competitors were not provided in the article. This significant movement in shares highlights the impact of clinical data releases on stock performance in the pharmaceutical sector. Investors should note the responsiveness of biotech stocks to trial results, as successful data can lead to sharp increases in market value.
Read More: Viking Therapeutics (VKTX) Shares Soar on Obesity Drug Data Release
Eli Lilly (LLY) Sees 700,000 Seniors Start GLP-1 Treatments
Eli Lilly CEO Dave Ricks reported that since the launch of Medicare coverage for obesity drugs in July, 700,000 new seniors have begun GLP-1 treatments, with 70% opting for Lilly medications. The coverage allows eligible seniors to access weight loss drugs for a $50 monthly co-pay. Lilly's Zepbound and Foundayo are noted as leading choices among patients, with one-third of new oral GLP-1 patients using Foundayo. The increase in patients shows significant market expansion for obesity treatments, which potentially benefits Eli Lilly (LLY) significantly.
Read More: Eli Lilly (LLY) Sees 700,000 Seniors Start GLP-1 Treatments
Eli Lilly (LLY) Price Target Increased to $1,400, Analysts See 25% Upside
On September 15, Berenberg upgraded Eli Lilly and Company (NYSE: LLY) from Hold to Buy, raising its price target from $1,220 to $1,400. Analysts predict about 25% upside, citing strong investment returns and growth in obesity treatments. Eli Lilly's recent investments total around $60 billion, with more than 25 business development deals made this year. The company faces risks, including US drug pricing reforms and potential competition that may impact growth. This matters to investors as higher price targets suggest analysts expect the stock to perform well.
Read More: Eli Lilly (LLY) Price Target Increased to $1,400, Analysts See 25% Upside
AbbVie (ABBV) vs. Eli Lilly (LLY): Insights for 2026 Investors
In FY 2025, AbbVie Inc (NYSE:ABBV) reported revenue of nearly $61.2 billion, growing 8.7% from the previous year, with net income around $4.3 billion. Eli Lilly and Co (NYSE:LLY) achieved revenue of approximately $65.2 billion, a significant increase of 45% year-over-year, and net income around $20.6 billion. AbbVie's revenue is heavily reliant on Skyrizi and Rinvoq, while Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, significantly contribute to its growth. Investors should note the differing risk profiles, with AbbVie facing patent expiration pressures and price reductions affecting certain products, which may influence investment choices.
Read More: AbbVie (ABBV) vs. Eli Lilly (LLY): Insights for 2026 Investors
Eli Lilly (LLY) Receives UK Approval for Orforglipron Weight Diabetes Drug
The UK has approved Eli Lilly's (LLY) drug orforglipron for the treatment of weight management and diabetes. This approval is significant as it may impact market competition in the weight loss and diabetes drug sectors. The decision reflects a growing trend towards medication solutions for these conditions. Investors may see movements in Eli Lilly's stock as this development could enhance the company's position in the healthcare market.
Read More: Eli Lilly (LLY) Receives UK Approval for Orforglipron Weight Diabetes Drug
Eli Lilly (LLY) Raises Price Target After Positive Quarter Results
Eli Lilly (LLY) announced an increase in its price target following a successful quarter where it beat earnings expectations. Specific figures from the earnings report were not mentioned, but the beat-and-raise indicates stronger-than-expected performance. This shift in outlook could enhance investor confidence and attract more market interest in LLY shares. For ordinary investors, this highlights a potentially lucrative growth opportunity based on Eli Lilly's ongoing success in its respective market.
Read More: Eli Lilly (LLY) Raises Price Target After Positive Quarter Results
Lilly's Mounjaro and Zepbound Sales Surge Over Novo Nordisk
Lilly's drugs Mounjaro and Zepbound are experiencing significant sales growth, which boosts their competitive position against Novo Nordisk's offerings. This surge may impact market dynamics as these products gain traction among consumers. The exact sales figures for Mounjaro and Zepbound are not specified; however, their escalating performance is acknowledged. This is essential for investors as increased sales could signal a shift in market share between Lilly and its competitors like Novo Nordisk (NVO).
Read More: Lilly's Mounjaro and Zepbound Sales Surge Over Novo Nordisk
S&P 500 Reaches New Highs; Arista (ANET) and Eli Lilly (LLY) Surges
Dow Jones futures increased as the S&P 500 reached new highs. Notably, Arista Networks (ANET) and Eli Lilly (LLY) saw significant gains. SpaceX and AMD experienced declines amid this market movement. These shifts may indicate varying sector performances and investor sentiment, with implications for future trading strategies and market trends.
Read More: S&P 500 Reaches New Highs; Arista (ANET) and Eli Lilly (LLY) Surges
Eli Lilly (LLY) and SpaceX Stocks Move Significantly Premarket
Eli Lilly (LLY) and other notable stocks like SpaceX, AMD, and Disney experienced significant movements in the premarket. Specific price changes were not shared in the article, but such premarket activity often reflects investors' reactions to news or earnings reports. The performance of these stocks could influence overall market momentum once trading opens. Investors should monitor these developments as they may affect market sentiment and trading volumes.
Read More: Eli Lilly (LLY) and SpaceX Stocks Move Significantly Premarket
Eli Lilly (LLY) Stock Rises 7% Year-to-Date with Major Catalysts Ahead
Eli Lilly (NYSE: LLY) has increased 7% since January 2026, underperformed compared to the broader market. In Q1 2026, sales surged 56% year-over-year, largely from its GLP-1 drug sales, with Mounjaro up 125% and Zepbound up 80%. The company is preparing to submit a Biologics License Application for retatrutide, its next product, to the FDA early next year, targeting a 2027 launch. Eli Lilly's upcoming earnings release on August 5 may affect stock performance, especially since it currently has a high P/E ratio of 34 times earnings, indicating a potential price adjustment. This information matters for investors evaluating potential entry points in LLY stock.
Read More: Eli Lilly (LLY) Stock Rises 7% Year-to-Date with Major Catalysts Ahead
State Street Healthcare ETFs XLV and XBI: Cost, Performance Comparison
The State Street Health Care Select Sector SPDR ETF (XLV) has an expense ratio of 0.08% and a dividend yield of 1.6%, with a recent share price of approximately $163.52. In contrast, the State Street SPDR S&P Biotech ETF (XBI) has an expense ratio of 0.35% and a dividend yield of 0.4%, priced around $151.46. XLV includes large-cap stocks such as Eli Lilly (NYSE:LLY) at 15.97% and Johnson & Johnson (NYSE:JNJ) at 10.67%. This comparison of cost and performance illustrates different investment strategies, affecting investor choices and asset allocations.
Read More: State Street Healthcare ETFs XLV and XBI: Cost, Performance Comparison
XLV vs PBE: Comparing Two Healthcare ETFs for Investors
The State Street Health Care Select Sector SPDR ETF (XLV) has an expense ratio of 0.08% and offers a yield of 1.6%, while the Invesco Biotechnology & Genome ETF (PBE) has a 0.58% expense ratio and a yield of 1.7%. XLV includes 60 holdings like Eli Lilly & Co (NYSE:LLY) at 16.5% and Johnson & Johnson (NYSE:JNJ) at 10.6%. In contrast, PBE holds 30 companies, with Vertex Pharmaceuticals (NASDAQ:VRTX) at 5.2% and Biogen Inc (NASDAQ:BIIB) at 5.1%. This comparison helps investors weigh low-cost sector exposure versus targeted growth potential in biotechnology.
Read More: XLV vs PBE: Comparing Two Healthcare ETFs for Investors
JPMorgan Recommends Eli Lilly, AbbVie, Danaher as Top Healthcare Stocks
JPMorgan has identified Eli Lilly, AbbVie, and Danaher Corporation as top picks within the healthcare sector. Investors are currently overlooking these stocks, which may present buying opportunities. The recommendation suggests potential growth in these companies as market dynamics shift. This could lead to increased interest and investment in these healthcare stocks, impacting their market performance positively for investors. Eli Lilly (LLY), AbbVie (ABBV), and Danaher (DHR) are highlighted for consideration.
Read More: JPMorgan Recommends Eli Lilly, AbbVie, Danaher as Top Healthcare StocksEli Lilly Delays FDA Filing for Retatrutide Weight-Loss Drug
Eli Lilly (LLY) announced that it will file for approval of its next-generation weight-loss drug, retatrutide, in 2027 after successfully completing two more trials. In clinical studies, retatrutide helped adults with diabetes or heart disease lose an average of 56 pounds, with some patients losing up to 20 percent of their weight. This delay in filing could impact Eli Lilly's market strategy and influence investor sentiment on the company's long-term prospects. Investors should be aware that the approval delay may affect stock performance in the near term.
Read More: Eli Lilly Delays FDA Filing for Retatrutide Weight-Loss Drug
Trump's Generic Drug Tariffs to Hit 100% by August 2028
President Donald Trump announced that generic drugs imported into the U.S. will face a 100% tariff starting in August 2028, rising to 200% in August 2029, after an initial two-year period with zero tariffs beginning August 1, 2026. This phased tariff schedule aims to incentivize domestic production of generic drugs. The U.S. imports nearly 50% of its generics from India, which significantly relies on the U.S. market for pharmaceutical exports. Ordinary investors should monitor these changes as they may impact the profitability and operations of major drugmakers like Eli Lilly and Pfizer (PFE).
Read More: Trump's Generic Drug Tariffs to Hit 100% by August 2028
Novo Nordisk Sues Eli Lilly Over Weight Loss Drug Ad Claims
Novo Nordisk filed a lawsuit against Eli Lilly on July 21, 2026, alleging that advertisements for Eli Lilly's obesity drug Zepbound and diabetes drug Mounjaro mislead consumers by using outdated data. The lawsuit seeks a permanent court order to stop the ads and financial damages after Lilly did not respond to a cease-and-desist letter. Novo claims their 7.2-milligram high-dose version of Wegovy shows average weight loss of 47 pounds, comparable to Zepbound's performance. This legal action comes as Novo fights to regain market share lost to Lilly after surpassing over 3 million U.S. prescriptions for its weight loss pill. For investors, this lawsuit highlights ongoing competition in the growing obesity drug market, projected to reach $120 billion by 2030.
Read More: Novo Nordisk Sues Eli Lilly Over Weight Loss Drug Ad Claims
Eli Lilly Acquires AtaiBeckley for Up to $3.8 Billion
Eli Lilly has announced its acquisition of AtaiBeckley for up to $3.8 billion, indicating a shift in Big Pharma's approach to psychedelic drugs for mental health. This acquisition follows positive clinical trial results for psychedelics, including Atai's BPL-003, a synthetic form of 5-MeO-DMT, currently in Phase 3 trials. The FDA has granted BPL-003 Breakthrough Therapy Designation, expediting its development for treatment-resistant depression, which affects around four million Americans. Analysts estimate that success in Phase 3 trials could open up a $1-2 billion market opportunity in this sector, signaling potential growth for investors interested in biotech innovations in mental health treatments.
Read More: Eli Lilly Acquires AtaiBeckley for Up to $3.8 Billion
Eli Lilly Stock Surge Driven by New Factors, Not Weight Loss
Eli Lilly's (LLY) stock price has been rising, attributed to developments unrelated to its weight loss treatments. Specific figures regarding stock price changes or trading volumes were not provided. This surge signifies investor focus on alternative drivers for growth, indicating a potential shift in market sentiment. Understanding these underlying factors could be crucial for investors as they navigate Eli Lilly's performance in the volatile healthcare market.
Read More: Eli Lilly Stock Surge Driven by New Factors, Not Weight Loss
Lilly Nears Acquisition Deal for AtaiBeckley Drugmaker
Eli Lilly is reportedly close to finalizing a deal to acquire Atai Bechkley, a company involved in developing psychedelic drugs. This acquisition could enhance Lilly's portfolio in the emerging field of mental health treatments. Though details regarding the financials of the deal are not disclosed, such strategic moves are essential for companies like Lilly (LLY) as they seek to capitalize on new therapeutic areas. The potential market impact could position Lilly favorably as the industry evolves towards more innovative drug solutions.
Read More: Lilly Nears Acquisition Deal for AtaiBeckley Drugmaker
IBB Up 51% Yearly; Eli Lilly (LLY) Completes Four Acquisitions
The iShares Biotechnology ETF (IBB) has risen 51% over the last year and is up 16.06% year to date, compared to a 9.22% gain for the S&P 500. Eli Lilly (LLY) has announced four acquisitions in Q1 2026 and reported Q1 revenues of $19.80 billion, a 55.5% increase year over year. The company's Mounjaro revenue reached $8.66 billion, a 125% growth. Cramer expects an influx of deals in the biotech sector following changes in FDA leadership, making biotech an attractive sector for investors given current market conditions.
Read More: IBB Up 51% Yearly; Eli Lilly (LLY) Completes Four Acquisitions
Premarket Moves: Key Stocks Including AAPL, PEP, CRM, and LLY
This article highlights significant premarket stock movements for companies including AstraZeneca, PepsiCo (PEP), Salesforce (CRM), and Levi Strauss. Notable companies and their trading volumes during this period have not been specified. Such movements can indicate investor sentiment which may influence trading decisions later in the day. For ordinary investors, understanding which stocks are moving early can help inform buy or sell decisions as they navigate market dynamics.
Read More: Premarket Moves: Key Stocks Including AAPL, PEP, CRM, and LLY
Lilly (LLY) to Present Alzheimer's Research at London Conference
Eli Lilly (LLY) announced it will present new research on Alzheimer's at a conference in London. This presentation is part of their ongoing efforts to advance treatments for Alzheimer's disease. Lilly's research could influence market perceptions significantly, especially regarding healthcare investments. The results from such studies are important for investors monitoring the pharmaceutical sector.
Read More: Lilly (LLY) to Present Alzheimer's Research at London Conference
IHE vs PJP: Key ETF Metrics Include Expense Ratios and Dividends
The iShares U.S. Pharmaceuticals ETF (IHE) has an expense ratio of 0.38% and a dividend yield of 1.62%, while the Invesco Pharmaceuticals ETF (PJP) has a higher expense ratio of 0.57% and a dividend yield of 0.96%. IHE holds 56 positions, heavily concentrated in Eli Lilly (NYSE:LLY) at 24.2% and Johnson & Johnson (NYSE:JNJ) at 20.3%. In contrast, PJP features 29 companies with Eli Lilly at 5.4%. Investors' choice between IHE and PJP hinges on their comfort with company-specific risks within the pharmaceutical sector.
Read More: IHE vs PJP: Key ETF Metrics Include Expense Ratios and Dividends
Eli Lilly (LLY) selected for FDA's PreCheck pilot program
Eli Lilly (LLY) and Regeneron (REGN) are among the first seven companies selected for the FDA's PreCheck pilot program aimed at accelerating reviews of new pharmaceutical manufacturing facilities. The initiative allows regulators to review facilities during construction, potentially saving companies up to 14 months in review time. Lilly's facility in Lebanon, Indiana, and Regeneron's $2 billion site in Saratoga Springs, New York, are included in the program. This effort targets domestic drug production and involves companies producing biologic drugs and genetic medicines.
Read More: Eli Lilly (LLY) selected for FDA's PreCheck pilot program
Tesla (TSLA) Market Moves Amid Dow Jones Futures Analysis
Dow Jones futures are indicating potential volatility in the market. Eli Lilly (LLY) has shown significant gains, prompting discussions around strategic investment decisions. While specific trading volumes and percentages were not provided, the mention of market tipping points suggests a crucial moment for investors. Tesla (TSLA) is highlighted as a key focus in upcoming trading sessions, emphasizing its importance in the broader market context.
Read More: Tesla (TSLA) Market Moves Amid Dow Jones Futures Analysis
Lilly (LLY) Obesity Drugs Approach Major Milestone in Trials
Lilly's (LLY) obesity drug candidates are nearing significant milestones in clinical trials, which could have considerable market implications. Investors are particularly focused on the upcoming data release expected to influence the company's stock performance. The expected efficacy of these drugs could lead to a substantial increase in market share within the obesity treatment sector. As obesity rates rise globally, pharmaceuticals like those from Lilly are poised for rapid growth in demand.
Read More: Lilly (LLY) Obesity Drugs Approach Major Milestone in Trials
Cathie Wood Sells $26.65M Robinhood (HOOD), Buys $46.18M Eli Lilly
On June 18, Cathie Wood’s ARK Invest sold 275,572 shares of Robinhood (HOOD) worth $26.65 million and 239,267 shares of Roku (ROKU) valued at $33.01 million. The sales followed significant stock rallies driven by profit-taking after Robinhood's announcement of a 10% workforce cut and Roku's acquisition deal valued at $22 billion. Wood reinvested approximately $46.18 million into Eli Lilly (LLY) by acquiring 41,138 shares, indicating a shift towards new growth opportunities. This strategic repositioning highlights Wood's focus on potential upside stories rather than established rallies.
Read More: Cathie Wood Sells $26.65M Robinhood (HOOD), Buys $46.18M Eli Lilly
SpaceX (SPAC) Mega-IPO Drives Pharma Innovation in Orbit
Morgan Stanley estimates the space economy could exceed $1 trillion by 2040, with increasing commercial opportunities in the pharmaceutical sector. Redwire has developed the PIL-BOX, a micro-laboratory for growing uniform drug crystals in zero gravity, successfully testing 37 drug compounds. This technology aims to reduce drug viscosity, allowing easier administration and potentially fewer side effects. Collaborations with companies such as Eli Lilly and Bristol Myers Squibb highlight the growing interest in pharmaceutical applications in space, signaling a transformative trend for the industry.
Read More: SpaceX (SPAC) Mega-IPO Drives Pharma Innovation in Orbit
Wegovy Maintains Market Dominance Despite Eli Lilly GLP-1 Launch
Wegovy continues to lead the GLP-1 market among weight-loss medications, despite competition from Eli Lilly's Foundayo. Specific market share percentages or sales figures were not provided. This dominance highlights Wegovy's strong brand recognition and patient preference in a growing sector. The competitive landscape for GLP-1 medications may impact market valuations for companies involved in this space, including Eli Lilly (LLY).
Read More: Wegovy Maintains Market Dominance Despite Eli Lilly GLP-1 Launch
Eli Lilly (LLY) Acquires Vaccine Firms for $3.8 Billion Growth Strategy
Eli Lilly (LLY) reported approximately $12.8 billion in revenues for Q1 2026, with its key drugs Mounjaro and Zepbound experiencing year-over-year sales growth of 125% and 80%, respectively. The company has invested $3.8 billion to acquire Curevo, LimmaTech Biologics AG, and Vaccine Company to expand its presence in infectious diseases. Eli Lilly's current P/E ratio stands at 39x, significantly higher than the pharmaceutical sector average of 24x. This strategic move is seen as a way to diversify its portfolio as the patent protection on its GLP-1 drugs is time-limited.
Read More: Eli Lilly (LLY) Acquires Vaccine Firms for $3.8 Billion Growth Strategy
Eli Lilly (LLY) shares phase 3 data on weight loss drug retatrutide
Eli Lilly (LLY) released phase 3 clinical trial data for retatrutide, a triple agonist designed for weight loss. The drug demonstrated significant efficacy in reducing body weight among participants, but specific numerical results were not disclosed in the announcement. This development is crucial as it highlights LLY's commitment to expanding its product portfolio in the obesity treatment space. The market could respond positively if further details indicate strong potential for retatrutide in the pharmaceutical market.
Read More: Eli Lilly (LLY) shares phase 3 data on weight loss drug retatrutide
CVS (CVS) Restores Coverage of Zepbound, Adds Eli Lilly's Foundayo
CVS Health (CVS) announced the restoration of coverage for Eli Lilly's (LLY) Zepbound effective October 1 and will add the Foundayo obesity pill on June 1. This adjustment positions Lilly to compete equally with Novo Nordisk in the weight loss market, affecting an estimated 25 million to 30 million Americans. CVS aims for a 10% to 15% increase in savings across weight management treatments with the updated formulary. The decision follows a prior agreement with Novo Nordisk that made Wegovy the favored choice on CVS plans while previously excluding Zepbound.
Read More: CVS (CVS) Restores Coverage of Zepbound, Adds Eli Lilly's Foundayo
IHE vs IXJ: 39.7% vs 10% 1-Year Returns in ETFs Comparison
The iShares U.S. Pharmaceuticals ETF (IHE) has posted a 1-year return of 39.70% as of May 20, 2026, while the iShares Global Healthcare ETF (IXJ) reported a return of 10.00%. Both funds have similar expense ratios, with IHE at 0.38% and IXJ at 0.40%. IHE's assets under management (AUM) stand at $883.6 million, compared to IXJ's $3.6 billion. Additionally, IHE has a higher dividend yield of 1.70% versus IXJ's 1.50%, indicating potential advantages for investors favoring domestic pharmaceutical exposure.
Read More: IHE vs IXJ: 39.7% vs 10% 1-Year Returns in ETFs Comparison
Eli Lilly (LLY) plans nearly $4 billion vaccine acquisitions
Eli Lilly (LLY) announced plans to acquire three companies for nearly $4 billion, intending to enhance its research efforts in infectious diseases. The acquisition includes Curevo for $1.5 billion, LimmaTech Biologics at $780 million, and Vaccine Company for $1.55 billion. Following this announcement, Eli Lilly's shares increased by 1.3% in premarket trading. The company's strategy emphasizes disease prevention at its source. These moves could impact the company's market position in the growing vaccine sector.
Read More: Eli Lilly (LLY) plans nearly $4 billion vaccine acquisitions
Eli Lilly (LLY) Stock Rating Reiterated Amid Gene Therapy Progress
Leerink has reiterated its stock rating for Eli Lilly (LLY), highlighting the company's ongoing advancements in gene therapy. Although specific data points or numerical targets were not disclosed in the article, the emphasis on progress suggests potential future benefits for LLY stock. The continuation of this rating indicates confidence among analysts regarding LLY's pipeline competitiveness and market position. Observers might consider this signal a bullish indicator for LLY's potential in the evolving biopharmaceutical sector.
Read More: Eli Lilly (LLY) Stock Rating Reiterated Amid Gene Therapy Progress
Eli Lilly (LLY) next-gen obesity drug achieves 28.3% weight loss
Eli Lilly (LLY) announced that its next-generation obesity drug, retatrutide, successfully completed a late-stage trial, showing a significant weight loss of 28.3% on average over 80 weeks. Approximately 45% of 2,500 trial participants achieved 30% or more weight loss, and around 65% reached a BMI below 30. Analysts had anticipated retatrutide to outperform Lilly's current weight loss drug, Zepbound, which achieves about 20% to 22% weight loss. The expected sales for retatrutide could reach $3.8 billion by 2030, highlighting its potential impact in the growing weight loss and diabetes market, projected to value around $100 billion by that time.
Read More: Eli Lilly (LLY) next-gen obesity drug achieves 28.3% weight loss
Eli Lilly (LLY) Price Target Raised to $1,400 Following Q1 Results
Eli Lilly and Company (LLY) received a price target increase to $1,400 from $1,350 by Barclays following strong first-quarter results. Goldman Sachs reiterated a Buy rating with a target of $1,283, stating that the stock's recent weakness seems overblown. The company revised its 2026 full-year revenue guidance to $82-85 billion, indicating a 28% growth from 2025. Additionally, LLY's non-GAAP EPS is estimated between $35.50 and $37, higher than previous estimates, reflecting robust performance across its therapeutic areas.
Read More: Eli Lilly (LLY) Price Target Raised to $1,400 Following Q1 Results
Novo Nordisk (NVO) high-dose Wegovy shows 27.7% weight loss
Novo Nordisk (NVO) announced that patients taking the high-dose 7.2-milligram version of Wegovy lost an average of 27.7% of their weight over 72 weeks in a recent trial. This data was presented at the European Congress on Obesity and could assist Novo in enhancing its competitive position against Eli Lilly's (LLY) Zepbound, which has shown weight loss of over 20%. The previous highest dose of Wegovy (2.4 mg) resulted in a 17% average weight loss. Approximately 25% of patients in the higher dose trial experienced early treatment response, achieving significant weight loss early in the treatment cycle.
Read More: Novo Nordisk (NVO) high-dose Wegovy shows 27.7% weight loss
Pfizer (PFE) Stock Down Over 50% from 2021 High Amid Challenges
Pfizer (PFE) stock is down over 50% from its 2021 high as demand for COVID vaccines decreases. The company is facing headwinds, including upcoming patent cliffs that could lead to revenue declines for key drugs. Despite this, Pfizer maintains a 6.4% dividend yield, with management stating that supporting the dividend is a key corporate goal. The company has taken steps to pivot towards GLP-1 weight-loss drugs and continues to develop its portfolio in oncology and migraine treatments, which could improve its market position in the future.
Read More: Pfizer (PFE) Stock Down Over 50% from 2021 High Amid Challenges
Eli Lilly (LLY) Reports 56% Revenue Growth, Raises 2026 Outlook
Eli Lilly and Co (NYSE:LLY) announced Q1 2026 results, with adjusted earnings per share at $8.55, exceeding analyst estimates of $6.66 to $6.97. Revenue reached $19.8 billion, surpassing expectations of $17.4 billion to $17.8 billion, indicating a 56% year-over-year increase. The company raised its 2026 revenue outlook to between $82 billion and $85 billion, up from $80 billion to $83 billion. This growth is primarily driven by increased prescription volumes for its GLP-1 medications, despite lower pricing realizations, and the recent FDA approval of Foundayo is expected to further expand access to treatments.
Read More: Eli Lilly (LLY) Reports 56% Revenue Growth, Raises 2026 Outlook
Premarket Stocks: Meta, Eli Lilly, Caterpillar and Amazon Update
Premarket trading saw significant movements with stocks like Meta and Amazon. Eli Lilly's (LLY) shares reportedly reacted to recent earnings reports, indicating a response to shifting market expectations. Caterpillar (CAT) is also in the spotlight, reflecting a broader interest in industrials amid changing economic conditions. These fluctuations are indicative of potential investor sentiment shifts and market impact as trading volumes adjust.
Read More: Premarket Stocks: Meta, Eli Lilly, Caterpillar and Amazon Update
Eli Lilly (LLY) Reports Q1 Earnings, Raises 2026 Revenue Outlook by $2B
Eli Lilly (LLY) reported Q1 earnings of $8.55 per share and revenue of $19.80 billion, surpassing estimates of $6.66 and $17.62 billion, respectively. The company raised its 2026 revenue guidance to $82-$85 billion from $80-$83 billion. Mounjaro's revenue increased 125% to $8.66 billion, while Zepbound generated $4.16 billion in U.S. sales, an 80% year-over-year rise. With a strong 60.1% share of the U.S. obesity market, the robust demand for its products underscores Lilly's market position despite price pressures.
Read More: Eli Lilly (LLY) Reports Q1 Earnings, Raises 2026 Revenue Outlook by $2B
Eli Lilly (LLY) Reports $12.9 Billion in GLP-1 Drug Sales
Eli Lilly (LLY) reported sales of $12.9 billion from its GLP-1 drugs every three months. The company stated that the tirzepatide franchise had a strong quarter, indicating significant market demand. This growth reflects the increasing adoption of these drugs as part of diabetes treatment. The positive sales performance could impact investor sentiment and market positioning for LLY as it continues to expand in the pharmaceutical sector.
Read More: Eli Lilly (LLY) Reports $12.9 Billion in GLP-1 Drug Sales
Novartis (NVS) drug trials target Lp(a) for heart disease prevention
Novartis (NVS), Amgen (AMGN), and Eli Lilly (LLY) are conducting late-stage trials for drugs aimed at reducing lipoprotein(a) or Lp(a) levels to prevent heart attacks. Current experimental drugs are shown to reduce Lp(a) by over 80%. Consensus estimates suggest these drugs could generate annual sales of $5.6 billion by 2032. The first results from Novartis' Phase 3 Horizon trial are expected later this year, which will significantly influence the market potential of these therapies.
Read More: Novartis (NVS) drug trials target Lp(a) for heart disease prevention
Eli Lilly (LLY) Plans $7B Acquisition, P/E at 40 Amid Growth
Eli Lilly (LLY) announced plans to acquire Kelonia Therapeutics for approximately $7 billion, a move intended to strengthen its gene therapy pipeline. The company reported a year-over-year revenue increase of 43% and earnings per share growth of 51% during the fourth quarter. Its current forward-looking price-to-earnings (P/E) ratio stands at 40, below its five-year average of 56. With health spending growing by 7.2% from 2023 to 2024, managing competition in the weight-loss sector remains crucial for Lilly's future growth.
Read More: Eli Lilly (LLY) Plans $7B Acquisition, P/E at 40 Amid Growth
Pfizer (PFE) GLP-1 Drug Shows 10%-12% Weight Loss in Trials
Pfizer (PFE) has reported positive results from its GLP-1 drug PF-08653944, which shows weight loss of 10% to 12% by week 28 in Phase 2b trials. This drug features a monthly injection regimen, compared to the weekly doses of competitors like Novo Nordisk's Wegovy and Eli Lilly's Zepbound, which may increase patient adherence. The weight loss drug market is projected to grow at nearly 25% annually through 2035, indicating strong competitive potential for Pfizer. As alternatives emerge, the dynamics of the anti-obesity drug market may be shifting, impacting shares of incumbents like NVO and LLY.
Read More: Pfizer (PFE) GLP-1 Drug Shows 10%-12% Weight Loss in Trials
Eli Lilly (LLY) sees GLP-1 windfall, Honeywell (HON) divests unit
Eli Lilly (LLY) has reported significant financial benefits from its GLP-1 drug line, although specific figures are not detailed. Honeywell (HON) has made the strategic decision to divest a lower-margin unit, aiming to enhance overall profitability. This move could impact both companies' profit margins as LLY capitalizes on a high-demand market while HON restructures its operations. The market may see a shift as investors evaluate the potential growth of LLY and the implications of HON's divestiture.
Read More: Eli Lilly (LLY) sees GLP-1 windfall, Honeywell (HON) divests unit
Lilly (LLY) obesity pill reduces cardiovascular risks in trial
Eli Lilly (LLY) announced that its Foundayo obesity pill met its trial goals by reducing the risk of major cardiovascular events by 16% in over 2,700 adults with type 2 diabetes. Compared to insulin glargine, patients taking Foundayo experienced a 57% lower risk of death from any cause. Additionally, those on Foundayo had greater reductions in blood sugar and weight, unlike patients on insulin glargine who gained weight. Eli Lilly plans to seek U.S. approval for Foundayo for type 2 diabetes by the end of Q2.
Read More: Lilly (LLY) obesity pill reduces cardiovascular risks in trial
Eli Lilly (LLY) market share drops to 56% in India as generics flood
Eli Lilly (LLY) saw its market share in India's GLP-1 weight-loss drug category decline to 56% in March from 61% in February, according to Pharmarack data. Meanwhile, Novo Nordisk (NVO) maintained a steady 25% market share despite the influx of generic semaglutide drugs following the expiration of its patent last month. The launch of 26 brands by 13 Indian generic companies is significantly impacting sales for Eli Lilly's higher-priced tirzepatide products. As generic options become more affordable, the competitive landscape for weight-loss treatment in India is changing rapidly, likely benefiting Novo Nordisk in the long run.
Read More: Eli Lilly (LLY) market share drops to 56% in India as generics flood
Senator Angus King Jr. Sells $1,000 to $15,000 in Autodesk (ADSK)
Senator Angus King Jr. (I-Maine) disclosed selling several stocks on February 13, 2026, including Autodesk (ADSK), Blackstone (BX), Eli Lilly (LLY), Meta Platforms (META), Microsoft (MSFT), Netflix (NFLX), On Holding (ONON), PayPal Holdings (PYPL), and Uber Technologies (UBER), with each transaction amounting to $1,000 to $15,000. All of these trades were marked as full sales of his positions. King's stock transactions total approximately $1.8 million since 2014, comprising around 125 trades. The senator still holds several other positions in his portfolio, which were not part of this sale.
Read More: Senator Angus King Jr. Sells $1,000 to $15,000 in Autodesk (ADSK)More Health Care stocks
Frequently asked questions
Is Eli Lilly and Company in the S&P 500?
Yes. Eli Lilly and Company trades as LLY and is a member of the S&P 500. The index lists it in the Health Care sector.
What sector is LLY in?
LLY sits in the Health Care sector of the S&P 500.
Where can I find the latest LLY news?
Right here. This page collects recent LLY news and market analysis. Every story gets an AI summary and a bullish, bearish or neutral tag.
What is Eli Lilly and Company's stock price?
LLY last traded at about $1,251.61. Prices move all through the session, so this is the latest quote rather than a live one.
What is Eli Lilly and Company's market cap?
LLY is worth roughly $1.12T. Market cap is the share price times the number of shares outstanding.
What is LLY's P/E ratio?
LLY trades at a trailing P/E ratio of about 42.0. The ratio compares the share price with earnings per share over the past year.